Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab.

Cancer Med · 2023 · PMC10166927 · PMID 36789624

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

It showed a trend of a longer OS in patients with prior trastuzumab use than those without prior trastuzumab use (median, 8.3 months vs. 4.8 months). 43 The KEYNOTE‐811 trial evaluating the combination of anti‐PD‐1 antibody and HER2‐blockade plus chemotherapy showed remarkable ORR of 74.4%. 44 Meanwhile, it

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.